Sign in

CIK 0001434316

  • Non-accelerated filer
  • Smaller reporting company

FATE THERAPEUTICS INC

Sign in to watch
Ticker
FATE
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
651311552
Phone
+1 858-875-1803
Business address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$13,525
in 1 filing

Net −$13,525. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Adawi Kamal −$14K Chief Financial Officer sold 7% of stake

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2022-01-21 Wolchko J Scott President and CEO Option exercise · Stock Option (Right to Buy) −10,000 76,246
2022-01-21 Wolchko J Scott President and CEO Option exercise +10,000 $2.70 $27K 441,546
2022-01-21 Wolchko J Scott President and CEO Sale −10,000 $38.02 $380K 431,546
2022-01-21 Wolchko J Scott President and CEO Option exercise · Stock Option (Right to Buy) −10,000 $2.70 $27K 89,446
2022-01-20 Wolchko J Scott President and CEO Option exercise +30,000 $2.70 $81K 461,546
2022-01-20 Wolchko J Scott President and CEO Option exercise · Stock Option (Right to Buy) −30,000 86,246
2022-01-20 Wolchko J Scott President and CEO Option exercise +30,000 $2.73 $82K 461,546
2022-01-20 Wolchko J Scott President and CEO Sale −30,000 $40.21 $1.2M 431,546
2022-01-20 Wolchko J Scott President and CEO Option exercise · Stock Option (Right to Buy) −30,000 $2.73 $82K 20,000
2022-01-11 Wolchko J Scott President and CEO Sale −10,047 $48.50 $487K 436,065
2022-01-11 Wolchko J Scott President and CEO Sale −4,519 $49.07 $222K 431,546
2022-01-11 TAHL CINDY General Counsel and Secretary Sale −4,883 $48.46 $237K 156,385
2022-01-11 TAHL CINDY General Counsel and Secretary Sale −536 $49.15 $26K 155,849
2022-01-11 Valamehr Bahram Chief R&D Officer Sale −4,152 $48.44 $201K 146,950
2022-01-11 Valamehr Bahram Chief R&D Officer Sale −418 $49.12 $21K 146,532
2022-01-11 Dulac Edward J III Chief Financial Officer Sale −1,380 $48.25 $67K 109,024
2022-01-11 Dulac Edward J III Chief Financial Officer Sale −390 $49.16 $19K 108,634
2022-01-11 Chu Yu-Waye Senior VP Clinical Development Sale −3,547 $48.44 $172K 122,211
2022-01-11 Chu Yu-Waye Senior VP Clinical Development Sale −418 $49.10 $21K 121,793
2022-01-10 Wolchko J Scott President and CEO Sale −13,161 $46.36 $610K 467,107

Page 13 of 26 · 503 trades